Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.
wherein R
2
, R
3
R
4
, R
5
and R
6
are defined herein.
Photocatalytic aerobic decarbonylative C–C coupling/alkylations of N-heteroarenes with aldehydes have been disclosed for the first time.
首次披露了N-杂环烃与醛的光催化空气氧化脱羰基C-C偶联/烷基化反应。
ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
申请人:Enanta Pharmaceuticals, Inc.
公开号:US20170304272A1
公开(公告)日:2017-10-26
The present invention provides compounds of Formula I,
pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
A visible‐light‐mediated photoredoxMinisci‐typealkylation with ethers as the alkylating reagent is reported. User‐friendly LiBr has been found to be the key promoter for this radical coupling. The reaction exhibits broad functional group tolerance for both C2 and C4 couplings/alkylations of quinolines. Mechanistic studies suggest that the bromide additive could not only dramatically enhance the reaction